Gleevec generic
Gleevec is an anti-cancer drug owned by Novartis. The main active ingredient is imatinib mesylate. The drug was first authorized for market use on May 10, 2001.
When will Gleevec generic be available?
The generic version of Gleevec could potentially be released after June 19, 2022. This date marks the expiration of patent US6958335*PED, which pertains to the treatment of gastrointestinal stromal tumors.
Gleevec uses
imatinib mesylate, the active ingredient in Gleevec, is used in the treatment of cancer, particularly gastrointestinal stromal tumors. The drug works by blocking the action of an abnormal protein that signals cancer cells to multiply.
Gleevec patent expiration
Gleevec has a total of 1 drug patent, has already expired. The patent, US6958335*PED, which pertains to the treatment of gastrointestinal stromal tumors, will expire on June 19, 2022. Gleevec's generic release is expected subsequent to this date. Below are the details of the patent: